Jatt Ii Acquisition CORP

Talawar Therapeutics and JATT II Acquisition Corp. have entered into a definitive business combination agreement to form a publicly listed biotechnology company focused on developing bispecific antibodies for immunology and inflammatory diseases.

Talawar Tx Inc. CEO Marc Schegerin discussed the company's lead asset, TALA-125, an IL-18/IL-13 bispecific antibody for atopic dermatitis, highlighting its potential to break efficacy ceilings and its streamlined development path.

Talawar Tx Inc. details its lead bispecific antibody candidate, TALA-125, targeting IL-13 and IL-18 for immunology and inflammation diseases, with a planned Phase 1 trial start in Q1 2027.

JATT II Acquisition Corp. reports changes in beneficial ownership, with CEO Someit Sidhu's indirect holdings adjusted due to share forfeiture.

JATT Ventures II L.P. reports a forfeiture of 225,000 ordinary shares in JATT II Acquisition Corp. due to over-allotment option expiration.

Talawar Therapeutics is merging with JATT II Acquisition Corp in a SPAC deal, aiming to raise $285 million to advance its eczema asset TALA-125.

JATT II Acquisition Corp and Talawar Tx Inc. have entered into a business combination agreement, with JATT II becoming an indirect wholly-owned subsidiary of Talawar Tx Inc.

JATT II Acquisition Corp. has filed an amendment to its Schedule 13D, correcting previously filed information regarding the citizenship of Someit Sidhu and reaffirming beneficial ownership details.

JATT II Acquisition Corp. has filed a Schedule 13D detailing beneficial ownership of 23.10% of ordinary shares by JATT Ventures II L.P. and its CEO, Someit Sidhu, highlighting their active role in pursuing a business combination.

ADAR1 Capital Management, LLC and its manager Daniel Schneeberger have jointly filed a Schedule 13G, reporting beneficial ownership of 417,724 Ordinary Shares, representing 5.4% of the outstanding shares of JATT II Acquisition Corp.

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D. and Ms. Lillian Nordahl, has reported beneficial ownership of 500,000 ordinary shares, representing 6.23% of JATT II Acquisition Corp.

Atika Capital Management LLC and Brad Farber have jointly filed a Schedule 13G, disclosing a beneficial ownership of 5.1% in JATT II Acquisition Corp.

Balyasny Asset Management L.P. and affiliated entities have disclosed beneficial ownership of 500,000 shares, representing 6.23% of JATT II Acquisition Corp's common stock.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 500,000 ordinary shares, representing 6.2% of the class, in JATT II Acquisition Corp.